Accelerating drug development through repurposed FDAApproved drugs for COVID-19: Speed is important, not haste

James T. Gord, Kaushiki Mazumdar, Noton K. Dutt

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Article numbere00857-20
JournalAntimicrobial agents and chemotherapy
Issue number8
StatePublished - Aug 2020


  • Antiviral drugs
  • COVID-19
  • Coronavirus disease 2019
  • FDA-approved drugs
  • Hostdirected therapy
  • Pathogen-directed therapy
  • SARS-CoV-2
  • Severe acute respiratory syndrome coronavirus-2
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this